Clinical Trials Logo

Depression clinical trials

View clinical trials related to Depression.

Filter by:
  • Terminated  
  • Page 1 ·  Next »

NCT ID: NCT03643159 Terminated - Schizophrenia Clinical Trials

A Trial to Measure the Difference in All-cause Hospitalizations for Patients Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder

Start date: June 29, 2018
Phase: Phase 4
Study type: Interventional

A pragmatic clinical trial (Main Study) to assess the difference between all-cause hospitalizations in patients using Abilify MyCite versus virtual matched controls. Eligible patients will enter a screening period of up to 13 days. At enrollment, patients will receive treatment with Abilify MyCite for 3 months and discontinue the use of Abilify MyCite during the following 3 months (and the patient continues with oral aripiprazole or other appropriate treatment). Thereafter, the patient has the option to start and stop Abilify MyCite (up to 6 months of Abilify MyCite) per the joint decision of the patients with their study physician. A parallel exploratory study will utilize a different set of physicians and patients from the main study. Procedures for the exploratory study will be similar to those in the Main Study, with the exception that there will be 1-month intervals of Abilify MyCite use (and 1-month intervals of prohibition of Abilify MyCite use).

NCT ID: NCT03487198 Terminated - Clinical trials for Major Depressive Disorder

The Safety and Efficacy of Brexpiprazole as Adjunctive Therapy in the Treatment of Major Depressive Disorder

Start date: May 30, 2018
Phase: Phase 3
Study type: Interventional

This study is a multicenter, randomized, double-blind, placebo-controlled trial designed to assess the efficacy and safety of brexpiprazole as adjunctive therapy in the treatment of Major Depressive Disorder. A total of approximately 1100 subjects will be enrolled into the single-blind treatment for 6 weeks, and 480 incomplete responders will be randomized to brexpiprazole (2~3 mg) or placebo in a 1:1 ratio (approximately 240 subjects in each group), for treatment of 6 weeks.

NCT ID: NCT03471754 Terminated - Clinical trials for Mild to Moderate Depression

Pilot Study Using Transcranial Electrostimulation (TESA-HB) Therapy for the Treatment of Depressive Symptoms

Start date: September 26, 2017
Phase: N/A
Study type: Interventional

This pilot study uses TESA-HB therapy for treatment of depressive symptoms associated with mild and moderate depression episodes. Primary objectives of this pilot study are to demonstrate the safety of TESA-HB Therapy, and to investigate the efficacy of TESA-HB Therapy for depressive symptoms.

NCT ID: NCT03323073 Terminated - Clinical trials for Major Depressive Episode

Study of Functional Networks in Resting fMRI

Start date: December 14, 2011
Phase: N/A
Study type: Interventional

The primary purpose is to compare with resting fMRI the functional networks of rest (RTS) in unipolar depression and in bipolar depression. Hypothesis : the main objective of this work is to compare with the rest fMRI the Rest Functional Networks (RFN) in the unipolar depression and in the bipolar depression in order to identify specific biomarkers for each affection. The general hypothesis of this work is that intra- and inter RFN connectivity is different between bipolar patients and unipolar patients. Specifically the investigators assume that connectivity within the default mode network (including ventral mediofrontal cortex, subgenual cingulate cortex, inferior parietal cortex, posterior cingulate cortex) will be increased in unipolar patients compared to bipolar patients.

NCT ID: NCT03272555 Terminated - Depression Clinical Trials

WILD 5 Wellness: A 30-Day Intervention

Start date: September 5, 2017
Phase: N/A
Study type: Interventional

The purpose of this study is to explore the efficacy and feasibility of an integrated, prescriptive, and trackable wellness intervention combining five wellness elements including exercise, mindfulness, sleep, social connectedness, and nutrition in First Year Beloit College students self-selected into a wellness focused first year initiative.

NCT ID: NCT03151226 Terminated - Clinical trials for Respiratory Depression

OSA Screen Negative With Spinal Duramorph

Start date: August 3, 2015
Phase: N/A
Study type: Interventional

Non emergent scheduled cesarean sections will be consented to participate in this study of patients who have screened negative for obstructive sleep apnea and who are also BMI>/= 35 to have capnography monitoring postoperatively. The capnography and pulse oximetry will be initiated in the post anesthesia care unit and be worn for 12-24 hours after delivery. Data will be retrieved after that time period in a deidentified fashion. Medication usage will be reviewed as well as the standard of care information from the duramorph monitoring will be retrieved.

NCT ID: NCT03121937 Terminated - Depression Clinical Trials

Feasibility of a Technology-Based Treatment Support System

Start date: August 1, 2017
Phase: N/A
Study type: Interventional

This study aims to evaluate a technology-based treatment support system for patients undergoing the treatment of depression. The investigators will explore the usefulness of the technology-based treatment support system as an adjunct to psychotherapy for depression.

NCT ID: NCT03101540 Terminated - Clinical trials for Major Depressive Disorder in Pregnancy

Cytokines, PUFA Tissue Concentrations and Treatment Selection in Antenatal MDD

Start date: August 2011
Phase: Early Phase 1
Study type: Interventional

For a number of reasons women with major depressive disorder often discontinue conventional antidepressants when they become pregnant and prefer not to take them when depressive illness develops in the course of pregnancy. There is now considerable evidence that the administration of the omega-3 polyunsaturated fatty acid, eicosapentaenoic acid (EPA), as monotherapy has antidepressant effects. If it could be clearly established as effective such an approach would offer a valuable alternative for woman who are at risk for, or who develop, depressive disorder during pregnancy. Strongly positive placebo-controlled trials of EPA supplementation, though, co-exist with entirely negative ones. No clear reasons for these discrepancies have emerged but one possibility is that the samples studied have differed in the proportion of individuals likely to benefit from EPA supplementation. As there has been no effort to identify such individuals we propose to explore two groups of measures, both relevant to EPA's likely mechanisms of action, as potential tools for identifying individuals likely to benefit this treatment. Hypothesis: Among women who experience major depressive episodes during their first two trimesters of pregnancy, baseline measures of cytokine activity and erythrocyte PUFA concentrations will be associated, in an additive or interactive fashion, with subsequent improvement in depressive symptoms among women taking omega-3 PUFA supplementation.

NCT ID: NCT03101527 Terminated - Clinical trials for Major Depressive Disorder in Pregnancy

Open Trial Determining Antidepressant Effects of Omega-3 Supplementation During Pregnancy

Start date: May 2011
Phase: Early Phase 1
Study type: Interventional

The purpose of this study is to determine if omega-3 polyunsaturated fatty acids as a monotherapy have antidepressant effects during pregnancy. It will also provide pilot data pertaining to relationships between apparent response to omega-3 monotherapy and both plasma cytokine and erythrocyte essential fatty acid concentrations.

NCT ID: NCT03093025 Terminated - Clinical trials for Major Depressive Disorder

A Study to Evaluate the Safety and Efficacy of TS-121 as an Adjunctive Treatment for Major Depressive Disorder

Start date: July 3, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, and efficacy of TS-121 as an adjunctive treatment for patients with major depressive disorder with an inadequate response to current antidepressant Treatment (SSRI, SNRI or bupropion).